These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36126186)
41. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Kallini JR; Gabr A; Salem R; Lewandowski RJ Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186 [TBL] [Abstract][Full Text] [Related]
42. Induction of Contralateral Hepatic Hypertrophy by Unilobar Yttrium-90 Transarterial Radioembolization versus Portal Vein Embolization: An Animal Study. Liebl M; Pedersoli F; Zimmermann M; Schulze-Hagen M; Truhn D; Sieben P; von Stillfried S; Tschinaev A; Heinzel A; Kuhl CK; Bruners P; Isfort P J Vasc Interv Radiol; 2021 Jun; 32(6):836-842.e2. PubMed ID: 33689835 [TBL] [Abstract][Full Text] [Related]
43. Utility of Early Posttreatment PET/CT Evaluation Using FDG or Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448 [No Abstract] [Full Text] [Related]
44. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355 [TBL] [Abstract][Full Text] [Related]
45. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990 [TBL] [Abstract][Full Text] [Related]
46. Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases. Jia Z; Paz-Fumagalli R; Frey GT; Sella DM; McKinney JM; Wang W Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):899-905. PubMed ID: 31104533 [No Abstract] [Full Text] [Related]
47. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031 [TBL] [Abstract][Full Text] [Related]
48. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma. Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180 [TBL] [Abstract][Full Text] [Related]
49. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408 [TBL] [Abstract][Full Text] [Related]
50. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889 [TBL] [Abstract][Full Text] [Related]
51. Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. Bibok A; Kis B; Frakes J; Hoffe S; Zhang J; Jain R; Parikh N J Vasc Interv Radiol; 2022 Sep; 33(9):1061-1065. PubMed ID: 36049841 [TBL] [Abstract][Full Text] [Related]
52. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. Alonso JC; Casans I; González FM; Fuster D; Rodríguez A; Sánchez N; Oyagüez I; Burgos R; Williams AO; Espinoza N BMC Gastroenterol; 2022 Jul; 22(1):326. PubMed ID: 35780112 [TBL] [Abstract][Full Text] [Related]
53. Resin Versus Glass Microspheres for Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436 [TBL] [Abstract][Full Text] [Related]
54. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Zarca K; Mimouni M; Pereira H; Chatellier G; Vilgrain V; Durand-Zaleski I; Clin Ther; 2021 Jul; 43(7):1201-1212. PubMed ID: 34059326 [TBL] [Abstract][Full Text] [Related]
55. Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization. Currie BM; Nadolski G; Mondschein J; Dagli M; Sudheendra D; Stavropoulos SW; Soulen MC J Vasc Interv Radiol; 2020 Oct; 31(10):1627-1635. PubMed ID: 33004146 [TBL] [Abstract][Full Text] [Related]
56. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. Miller MD; Sze DY; Padia SA; Lewandowski RJ; Salem R; Mpofu P; Haste PM; Johnson MS J Vasc Interv Radiol; 2018 Jun; 29(6):867-873. PubMed ID: 29724518 [TBL] [Abstract][Full Text] [Related]